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Abstract
Background: Depressive symptoms are prevalent in patients with coronary artery disease (CAD). It is unclear,
however, how depressive symptoms change over time and the impact of these changes on long-term functional
outcomes. We examined the association between different trajectories of depressive symptoms over 1 year and
change in functional status over 30 months among patients undergoing coronary angiography.
Methods: This was a prospective cohort study of 350 patients aged 60 and older undergoing non-emergent
cardiac catheterization (October 2003–February 2007). A dynamic measure of significant depressive symptoms
(i.e., Geriatric Depression Scale score 5+) capturing change over 12 months was derived that categorized patients
into the following groups: (i) no clinically important depressive symptoms (at baseline, 6 and 12 months); (ii) baseline-
only symptoms (at baseline but not at 6 and 12 months); (iii) new onset symptoms (not at baseline but present at
either 6 or 12 months); and, (iv) persistent symptoms (at baseline and at either 6 or 12 month assessment). Primary
outcomes were mean change in Older Americans Resources and Services (OARS) instrumental (IADL) and basic
activities of daily living (BADL) scores (range 0–14 for each) across baseline (pre-procedure) and 6, 12, and
30 months post-procedure visits.
Results: Estimates for the symptom categories were 71 % (none), 9 % (baseline only), 8 % (new onset) and 12 %
(persistent). In adjusted models, patients with persistent symptoms showed a significant decrease in mean IADL and
BADL scores from baseline to 6 months (−1.32 [95 % CI −1.78 to −0.86] and −0.63 [−0.97 to −0.30], respectively) and
from 12 to 30 months (−0.79 [−1.27 to −0.31] and −1.00 [−1.35 to −0.65], respectively). New onset symptoms were
associated with a significant decrease in mean IADL scores at 6 months and from 6 to 12 months. Patients with no
depressive symptoms showed little change in scores whereas those with baseline only symptoms showed significant
improvement in mean IADL at 6 months.
Conclusions: Patients with persistent depressive symptoms were at greatest risk for worse functional status 30 months
following coronary interventions. Proactive screening and follow-up for depression in this population offers prognostic
value and may facilitate the implementation of targeted interventions.
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Background
In older hospitalized adults, depressive symptoms are
common and associated with a variety of adverse out-
comes including worse quality of life [1, 2], reduced phys-
ical function [3], caregiver burnout [4], and increased
mortality [5, 6]. Among older patients with coronary
artery disease (CAD), estimates for minor and major
depressive symptoms range from 30 to 45 % [7–9]. This
compares to a prevalence of about 15 % among
community-based samples of adults aged 60 years or older
[10]. In CAD patients, depressive symptoms represent an
independent risk factor for all-cause mortality and adverse
cardiovascular events [7, 11, 12]. Although baseline mea-
sures of depression have been linked to poorer functional
outcomes in older adults with CAD [13–15], most of this
research has failed to consider the dynamic nature of
depressive symptoms in this population or the associated
consequences for longer-term health and functional out-
comes. This is a significant knowledge gap as symptoms
of depression may be transient, episodic or persistent [16].
With increasing survival rates among older adults with
CAD undergoing coronary interventions [17], it is import-
ant to consider how the course of depressive symptoms
may impact long-term functional independence in this
vulnerable population.
In one of the few studies to explore this area, Sin and
colleagues demonstrated a significant association be-
tween increases in depressive symptoms over 5 years
and decreases in basic (but not instrumental) activities
of daily living among 658 older adults with stable coron-
ary heart disease [18]. In this study, changes in select
disease severity markers (including frequency of angina
and ejection fraction) were not found to be predictive of
change in functional status. As this study was limited to
older patients with stable disease and by an assessment
of depression at baseline and at the 5-year follow-up
only, further work to explore the trajectory and func-
tional consequences of depressive symptoms in older
patients undergoing coronary interventions is needed.
Emerging evidence suggests not all depressed patients
with CAD are at risk of adverse health outcomes. Patients
with new onset or persistent symptoms appear to be at
highest risk for mortality and cardiac events [11, 19–21].
Among older community-dwelling adults, those exhibiting
persistent depressive symptoms show an increased risk for
cognitive and functional decline [22–24]. In a previous
study of CAD patients undergoing coronary interventions,
we observed that participants with persistent depressive
symptoms had significantly greater declines at 30 months
in attention/executive function, learning/memory, verbal
fluency and global cognition [25]. Although others have
examined predictors and outcomes of trajectories in
depressive symptoms among patients with cardiovascular
disease [2, 18], the impact of different trajectories in
depressive symptoms assessed among CAD patients pre-
and post-coronary interventions on functional change
over a longer-term (beyond 1 year) remains to be ex-
plored. As we previously noted, while patients undergoing
coronary interventions would be expected to exhibit
significant variation in their symptoms, health status and
well-being over time [25, 26], the impact of such variation
on functional outcomes remain unknown.
Our aim was to examine the impact of change in clin-
ically significant depressive symptoms over 1 year on
long-term (30 month) change in instrumental (IADL)
and basic activities of daily living (BADL) among older
patients undergoing coronary catheterization who subse-
quently received coronary artery bypass graft (CABG)




The Calgary Cardiac and Cognition (3C) Study was a
prospective cohort investigation of the impact of neuro-
cognitive and psychological factors on quality of life and
functional status among older CAD patients undergoing
evaluation for coronary revascularization.
Between October 2003 and May 2007 a total of 374
subjects aged 60 years and older were enrolled at a
tertiary care hospital providing centralized cardiac ser-
vices for residents of southern Alberta, Canada. Patients
underwent coronary angiography (between October
2003 and February 2007) and post-catheterization, 128
underwent CABG surgery, 150 had PCI and 96 received
MT. Trained cardiovascular research nurses screened all
patients presenting for angiography for eligibility. Exclusion
criteria included age < 60 years, emergency catheterization,
prior revascularization and inability to provide informed
written consent or complete the assessment due to
language difficulties or severe cognitive and/or phys-
ical impairments. We purposefully oversampled those
scheduled to undergo CABG and PCI (a comparison
of our study sample to all eligible patients undergoing
coronary catheterization during our recruitment
period is available elsewhere) [25]. Ethics approval was
obtained from the Conjoint Health Research Ethics
Board, University of Calgary and informed consent
was obtained from all participants.
A comprehensive standardized assessment including
neuropsychological and physical performance tests, socio-
demographic items, health behavior, self-rated health,
activities of daily living and health-related quality of life
measures was administered at baseline (pre-procedure), 6,
12, and 30 months post-procedure by trained research
nurses or associates. Most (58 %) baseline assessments
were conducted in hospital with the remainder as well as
all follow-up assessments in the participant’s home. A
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trained psychometrician (blinded to patients’ clinical char-
acteristics) reviewed and scored all cognitive testing. A
structured interview with the patient’s identified informant
(including Section H of the Cambridge Mental Disorders
of the Elderly Examination-Revised [CAMDEX-R]) [27]
was administered at all follow-up assessments, where
possible. The study database was linked with the Alberta
Provincial Project for Outcome Assessment in Coronary
Heart Disease (APPROACH) [28], a comprehensive regis-
try of all patients undergoing cardiac catheterization in
the province, for baseline clinical characteristics and data
on repeat revascularization(s) and mortality during
follow-up. Three patients could not be linked because of
out-of-province catheterizations (n = 2) or missing hos-
pital records (n = 1). Specific details on the 3C assessment
battery, variable coding and data collection procedures
have been published elsewhere [25].
During the 30 months, 40 participants moved or with-
drew, 16 died and 7 subjects missed either the 6 or
12 month assessment but remained in the study (Fig. 1).
Loss to follow-up at 30 months was 11 % (40/374) of all
enrolled subjects. The number of participants with out-
come data at 6 and/ or 12 months and included in our
analyses was 350/374 (94 %).
Measurement of Depressive Symptoms
The 15-item Geriatric Depression Scale (GDS) [29, 30]
with a cut-point of ≥ 5 was used to define clinically im-
portant depressive symptoms. The GDS is a commonly
used screening test for depression in older adults with
established validity and reliability [31–33]. It is well
suited for medically ill older patients because of its focus
on non-somatic symptoms. As done in previous studies
[22, 25], we created a dynamic measure of significant de-
pressive symptoms with the following categories: (i) no
clinically important depressive symptoms (at baseline, 6
and 12 months); (ii) baseline-only symptoms (at baseline
but not at 6 and 12 months); (iii) new onset symptoms
(not at baseline but present at either 6 or 12 months);
and, (iv) persistent symptoms (at baseline and at either
the 6 or 12 month assessment).
Functional Outcomes
Instrumental (IADL) and basic (BADL) activities of daily
living were assessed with the Older Americans Re-
sources and Services (OARS) Multidimensional Func-
tional Assessment Questionnaire [34]. The IADL and
BADL items demonstrate good reliability and validity
and have been extensively utilized in past research on
older adults [31]. The seven IADL items assess the re-
spondent’s ability to use the telephone, travel distances
independently, go shopping, prepare meals, do house-
work, take medicines and handle finances. The seven
BADL items assess the respondent’s ability to feed self,
dress/undress, groom self, walk, transfer to/from bed,
bathe, and to use the bathroom. Response options were
coded as 2 (can perform independently); 1 (requires
some help/assistive device); or, 0 (is unable to perform
on his/her own). Total scores for both scales ranged
from 0 to 14, with lower scores indicating a higher level
of impairment. IADL and BADL were examined as both
continuous and binary (no vs. impairment [score of 0 or
1] in 1+ activities) variables.
Other Measures
The socio-demographic, health and lifestyle characteris-
tics of patients were assessed at baseline by study nurses
[25]. Education was self-reported and recorded as num-
ber of completed full-time years since kindergarten.
Anxiety was assessed with the State-Trait Anxiety Index
[35] (state only), with higher scores indicating greater
anxiety. Global cognitive performance was screened
using the Mini-Mental State Exam (MMSE) [36]. Raw
scores were used.
Baseline clinical data derived from the APPROACH
database [28] included: admission diagnosis, ejection
fraction, high risk coronary anatomy (i.e., double-vessel
CAD with proximal left anterior descending artery in-
volvement, any 3 vessel disease or left main disease),
Canadian Cardiovascular Society (CCS) angina class,
acute coronary syndrome, and disease history (cerebro-
vascular, congestive heart failure, peripheral vascular,
diabetes mellitus, hypertension, hyperlipidemia, pulmon-
ary, renal, malignancy, liver, gastrointestinal).
Fig. 1 Calgary Cardiac and Cognition (3C) Study Flow. Legend/Footnote:
Reproduced with permission from Archives of General Psychiatry. 2012.
69(3):244–255.25 Copyright © (2012) American Medical Association. All
rights reserved
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Missing Data, Value Assignment and Imputation
Two participants (with dementia at follow-up) unable to
complete the GDS were assigned GDS scores based on
CAMDEX Part H [27] caregiver questions about the
participant’s mood. Missing OARS data was rare with
approximately 0.36 % missing across all visits for each of
the individual IADLs and about 0.19 % missing for each
of the individual BADLs. In each case, a geriatrician
(DH) reviewed all data collected for the participant and
assigned a score based on previous and subsequent
OARS responses, current performance test results, cog-
nitive test results, and quality of life responses.
Statistical Analyses
Descriptive analyses were conducted to examine the
distribution of patients’ socio-demographic and clinical
characteristics overall and by depression status [25]. The
4-level categorical measure of depressive symptoms was
examined with regard to mean change in continuous
IADL and BADL scores between baseline and 6 months,
6 to 12 months, and 12 to 30 months using linear mixed
models with a random intercept (function lmer in the
lme4 package in R version 3.2.3) [37]. Restricted max-
imum likelihood (REML) was used to estimate the
model parameters. To account for the impact of baseline
covariates in changes over time, the models included
interactions between time and age, sex, and baseline
MMSE scores. We repeated these models also adjusting
for a comorbidity measure (derived from selected diag-
noses captured by the APPROACH database). As further
adjustment for comorbidity did not alter our findings,
we have presented the more parsimonious model
estimates in this paper. The results were summarized in
terms of generalized least squares (GLS) means with
95 % confidence intervals as well as mean differences
with 95 % confidence intervals.
Secondary analyses used generalized estimating equa-
tions with an exchangeable correlation structure (func-
tion geeglm in the geepack package in R version 3.2.3)
[37] to fit logistic regression models to evaluate changes
in proportions of patients with any ADLs after account-
ing for baseline age, sex, and MMSE.
Results
The mean age of our sample was 71.3 (SD 5.9) years and
73.7 % were male. Over 1 year, 248 (71 %) participants
exhibited no significant depressive symptoms, 32 (9 %)
had baseline-only symptoms, 28 (8 %) were new onset
cases (at 6 or 12 months), and 42 (12 %) showed persist-
ent symptoms. Table 1 presents a comparison of base-
line characteristics (and follow-up GDS scores) across
these four categories. There were relatively few meaning-
ful differences between the groups. Compared to sub-
jects without symptoms at any assessment: (i) those with
new onset symptoms were older, less educated, and
more likely to be living alone, have marked/unstable an-
gina, or an acute coronary syndrome; and, (ii) those with
persistent symptoms were more likely to report poor
self-rated health, have higher anxiety scores, and report
a history of diabetes, marked/unstable angina or an
acute coronary syndrome. Baseline mean MMSE scores
were significantly lower among all 3 depressive symptom
groups compared to those with no symptoms.
Among participants with new onset and persistent
depressive symptoms, there was an increase in the pro-
portion with any IADL impairment from baseline to
30 months. There was little change among those with
no depressive symptoms and a decrease in proportion
with any IADL impairment among patients with base-
line only symptoms (Table 2, for adjusted estimates
see Additional file 1: Fig. S1). There was a higher
proportion with any BADL impairment at 30 months
evident among subjects with new onset and persistent
symptoms (Table 2, for adjusted estimates see
Additional file 1: Fig. S2).
In models adjusted for age, sex and baseline MMSE
score, subjects with persistent depressive symptoms
showed a significant decrease in mean IADL and BADL
scores from baseline to 6 months (−1.32 [95%CI −1.78
to −0.86] and −0.63 [−0.97 to −0.30], respectively) and
from 12 to 30 months (−0.79 [−1.27 to −0.31] and −1.00
[−1.35 to −0.65], respectively) post-procedure (Tables 3
and 4; Figs. 2 and 3). Those with new onset depressive
symptoms showed a significant decrease in mean IADL
and BADL scores from baseline to 6 months (−0.80
[−1.37 to −0.24] and −0.84 [−1.25 to −0.43], respectively)
and in mean IADL score from 6 to 12 months (−0.99
[−1.56 to −0.42]) follow-up. Participants with baseline
only depressive symptoms showed a significant improve-
ment in mean IADL score from baseline to 6 months (0.62
[0.09 to 1.15]) and relative stability in mean IADL and
BADL scores across subsequent follow-up assessments.
Subjects exhibiting no depressive symptoms during the
1 year post-procedure showed no significant change in
mean IADL or BADL scores from baseline to 6 months or
from 6 to 12 months; however they exhibited a significant
but small decrease in mean IADL and BADL scores from
12 to 30 months post-procedure (−0.24 [−0.44 to −0.05]
and −0.16 [−0.30 to −0.02], respectively).
Discussion
This study is one of but a few to explore the association
between changes in depressive symptoms over time and
long-term functional status among older CAD patients
undergoing non-emergent catheterization. Patients with
persistent symptoms experienced a significant decrease
in mean IADL and BADL scores over the 30-month
follow-up period post-procedure. A significant (but
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Sociodemographic and Lifestyle Factors
Age: mean (SD) 70.1 (5.8) 71.0 (6.1) 74.3 (6.5) 71.7 (5.3) 0.03
Age 75+: n (%) 57 (23.0) 7 (21.9) 9 (32.1) 12 (28.6) 0.11
Male: n (%) 186 (75.0) 23 (71.9) 18 (64.3) 31 (73.8) 0.67
Education: mean (SD), y 13.2 (3.8) 11.5 (2.7) 11.4 (4.3) 12.2 (4.2) 0.01
Lives alone: n (%) 31 (12.5) 8 (25.0) 9 (32.1) 7 (16.7) 0.02
Current or past smoker: n (%) 176 (71.0) 23 (71.9) 20 (71.4) 30 (71.4) >0.99
Heavy drinker: n (%) 48 (19.4) 8 (25.0) 4 (14.3) 8 (19.0) 0.77
Treatment Group, n (%)
CABG 80 (32.3) 13 (40.6) 10 (35.7) 18 (42.9) 0.66
PCI 107 (43.1) 13 (40.6) 9 (32.1) 14 (33.3)
Medical Therapy 61 (24.6) 6 (18.8) 9 (32.1) 10 (23.8)
Clinical Characteristicsa n (%)
Admitted with stable angina
(vs MI, unstable angina and other)
168 (68.3) 19 (61.3) 16 (57.1) 24 (57.1) 0.37
Ejection Fraction <50 % 53 (21.5) 9 (29.0) 6 (21.4) 9 (21.4) 0.82
High risk coronary anatomyb 105 (42.7) 19 (61.3) 16 (59.3) 20 (48.8) 0.17
CCS angina class > II 104 (42.3) 19 (61.3) 18 (64.3) 26 (61.9) 0.01
Acute coronary syndrome 53 (21.5) 9 (29.0) 11 (39.3) 16 (38.1) 0.04
Medical Historya n (%)
Cerebrovascular disease 20 (8.1) 4 (12.9) 2 (7.1) 8 (19.0) 0.14
Congestive heart failure 22 (8.9) 3 (9.7) 5 (17.9) 3 (7.1) 0.45
Peripheral vascular diseasec 21 (8.6) 2 (6.3) 1 (3.6) 7 (16.7) 0.57
Diabetes Mellitus (Type I or II) 52 (21.1) 11 (35.5) 4 (14.3) 15 (35.7) 0.05
Hypertension 185 (75.2) 27 (87.1) 23 (82.1) 33 (78.6) 0.44
Hyperlipidemia 207 (84.1) 24 (77.4) 25 (89.3) 34 (81.0) 0.62
Pulmonary disease 48 (19.5) 7 (22.6) 8 (28.6) 13 (31.0) 0.31
Renal disease 5 (2.0) 2 (6.5) 1 (3.6) 2 (4.8) 0.45
Malignancy 12 (4.9) 1 (3.2) 2 (7.1) 3 (7.1) 0.84
Severe/debilitating liver disease 1 (0.4) 1 (3.2) 0 (0) 0 (0) 0.23
Severe/debilitating gastrointestinal disease 14 (5.7) 3 (9.7) 2 (7.1) 7 (16.7) 0.09
Additional Clinical Information
Baseline mean MMSE score (SD) 28.5 (1.3) 27.8 (2.0) 27.6 (2.3) 27.2 (2.6) <0.001
Previous stroke and/or TIA: n(%) 27 (10.9) 4 (12.5) 5 (17.9) 7 (16.7) 0.57
Self rated health-fair/poor: n(%)d 34 (13.8) 16 (50.0) 7 (25.0) 23 (54.8) <0.001
Anxiety level (STAI score): mean (SD)e 32.7 (9.7) 35.1 (9.2) 35.2 (10.2) 43.1 (10.2) <0.001
Baseline and Follow-up GDS Score
Baseline GDS scores, mean (SD) 1.76 (1.28) 6.22 (1.64) 2.39 (1.37) 7.60 (2.67) <0.001
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smaller) decrease in mean IADL and BADL scores
during selected assessment times over follow-up was
also evident among patients with new onset depressive
symptoms. In contrast, there was relative stability in
IADL and BADL functioning among patients with no
depressive symptoms or depressive symptoms at baseline
only. Among the latter group, there was a small but sig-
nificant improvement in mean IADL scores between
baseline and 6 months post-procedure.
The overall magnitude of change observed in our IADL
and BADL measures during the 30 months appears to ap-
proximate a clinically meaningful difference in functional
status [18, 38, 39]. In their recent study of depressive
symptoms among older adults with stable coronary heart
disease, Sin and colleagues [18] argued for the clinical
relevance of a 1-point decrease in comparable IADL and
BADL measures on the basis that a change of this magni-
tude would capture those needing assistance with an add-
itional activity (or shifting to complete dependence from
partial assistance for an activity).
Our findings are consistent with the hypothesis that
persistent or more severe depressive symptoms are asso-
ciated with worse outcomes in this patient population
[11, 19–21]. Although there is extensive literature link-
ing depression to disability among older community-
based adults [24] and medical patients [40], a unique
contribution of our work is the focus on the dynamic
nature of depressive symptoms in a CAD population
undergoing coronary interventions and subsequent risk
of long-term functional outcomes. An earlier publication
based on this cohort showed that participants with per-
sistent depressive symptoms (relative to those with no or
baseline-only symptoms) exhibited significantly greater
decline at 30 months in multiple cognitive domains,
including attention/executive functioning [25]. Executive
dysfunction would be expected to place patients at
heightened risk for greater functional disability [24, 41,
42]. In the current analyses, we show that persistent
symptoms also represent an independent risk factor for
long-term functional disability.
Table 1 Baseline (and follow-up GDS) Characteristics of 3C Subjects by Depressive Symptom Change over 1 Year (Continued)
6 Month GDS scores, mean (SD) 1.12 (1.18) 2.35 (1.33) 5.61 (2.96) 7.19 (3.05) <0.001
12 Month GDS scores, mean (SD) 1.18 (1.22) 1.78 (1.24) 4.26 (2.86) 6.90 (3.26) <0.001
30 month GDS scores, mean (SD) 1.20 (1.46) 3.11 (2.25) 3.41 (2.89) 7.70 (3.70) <0.001
Reproduced with permission from Archives of General Psychiatry. 2012. 69(3):244–255.25 Copyright © (2012) American Medical Association. All rights reserved
Abbreviations: GDS geriatric depression scale, CABG coronary artery bypass graft, PCI percutaneous coronary intervention, MI myocardial infarction, MMSE mini-mental
state examination, TIA transient ischemic attack, STAI, State-Trait Anxiety Inventory
aAPPROACH variables collected at time of catheterization, n = 246 patients in the group with no depressive symptoms and n = 31 in the group with symptoms at
baseline only, otherwise noted
bn = 27, n = 41 for the new onset and persistent groups respectively (high risk coronary anatomy)
cn = 245 for the no depressive symptoms group (peripheral vascular disease)
dn = 247 for no depressive symptoms group (self-rated health)
en = 246 for no depressive symptoms group (anxiety)
*F-test for continuous variables; chi-square test for categorical variables
Table 2 Percentage (95 % CI) of 3C Subjects with any IADL or BADL impairment at each assessment by Depressive Symptom
Change over 1 Year
Depressive symptom category
None Baseline only New onset Persistent
IADL impairment
Baselinea 16.9 (12.8–22.1) 53.1 (36.4–69.1) 28.6 (15.3–47.1) 35.7 (23.0–50.8)
6 Monthsb 21.0 (16.3–26.5) 25.8 (13.7–43.2) 50.0 (32.6–67.4) 50.0 (35.5–64.5)
12 Monthsc 16.2 (12.1–21.4) 25.0 (13.3–42.1) 44.4 (27.6–62.7) 54.8 (39.9–68.8)
30 monthsd 20.4 (15.6–26.1) 28.6 (15.3–47.1) 51.9 (34.0–69.3) 56.8 (40.9–71.3)
BADL impairment
Baselinea 5.2 (3.1–8.8) 12.5 (5.0–28.1) 10.7 (3.7–27.2) 23.8 (13.5–38.5)
6 Monthsb 8.2 (5.4–12.4) 16.1 (7.1–32.6) 35.7 (20.7–54.2) 33.3 (21.0–48.4)
12 Monthsc 9.2 (6.1–13.5) 21.9 (11.0–38.8) 33.3 (18.6–52.2) 38.1 (25.0–53.2)
30 Monthsd 10.6 (7.2–15.3) 17.9 (7.9–35.6) 37.0 (21.5–55.8) 51.4 (35.9–66.6)
Abbreviations: 3C calgary cardiac and cognition study, IADL instrumental activities of daily living, BADL basic activities of daily living
asample sizes are n = 248, n = 32, n = 28, n = 42 for none, baseline only, new onset and persistent groups, respectively
bsample sizes are n = 243, n = 31, n = 28, n = 42 for none, baseline only, new onset and persistent groups, respectively
csample sizes are n = 240, n = 32, n = 27, n = 42 for none, baseline only, new onset and persistent groups, respectively
dsample sizes are n = 226, n = 28, n = 27, n = 37 for none, baseline only, new onset and persistent groups, respectively
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Several implications can be drawn from our work.
First, depressive symptoms are not static among older
adults with CAD undergoing coronary interventions.
Some with clinically meaningful symptoms at baseline
improve, while others have persistent problems that are
associated with worse functional outcomes. The small
but significant improvement in mean IADL scores ob-
served between baseline and 6 months post-procedure
among patients with depressive symptoms at baseline
only illustrates this point. This sub-group may have
experienced transient depressive symptoms in response
to their health status pre-procedure or from anxiety
about their diagnosis and impending procedure. The im-
provement in their disease symptoms and/or anxiety
level post-procedure could explain both the absence of
continued depressive symptoms and their increased
likelihood for better functional status at 6 months. Our
findings provide a rationale for assessing depressive
symptoms at multiple time points (e.g., before and 6 or
12 months post-interventions). Information regarding
new onset or persistent depressive symptoms could be
used to delineate high-risk groups in need of targeted in-
terventions to prevent or slow functional decline. The
recognition of persistent symptoms may warrant greater
secondary prevention efforts. Patients with persistent
depressive symptoms may be at an increased risk for
non-adherence [43] and consequently may require
heightened surveillance. The significant improvement in
IADL scores observed for patients with depressive symp-
toms at baseline only, suggests the potential for clinical
interventions to alter functional trajectories.
Several possible mechanisms may explain why depres-
sive symptoms are associated with worse functional
status. Their presence could lead to functional limita-
tions. Experienced depression may decrease motivation
for, and reward from, physical and/or social activities
important for the maintenance of functional independ-
ence. This is consistent with the finding that depressed
patients are more difficult to engage in physical therapy,
often crucial for recovery of function [44]. Depressive
symptoms can amplify symptoms of medical illnesses
[45], or affect adherence to medication regimens [43],
worsening the course of various chronic conditions. Fur-
ther, depressive symptoms might affect functioning
through neuroendocrine and inflammatory mechanisms
[46]. It is possible that depression may negatively influ-
ence a patient’s perceptions of what they are able to do
[47], limiting their ability to participate in rehabilitation
Table 3 Generalized Least Squares Mean (95 % Confidence Interval) Change in IADLa Over Time, by Depressive Symptom Change
over 1 Year
Depression symptom category Mean Change from previous measure P-value
Estimate 95 % CI Estimate 95 % CI
Baseline
None 13.65 [13.44–13.86] N/A N/A N/A
Baseline only 12.80 [12.22–13.39] N/A N/A N/A
New onset 13.58 [12.94–14.21] N/A N/A N/A
Persistent 13.03 [12.51–13.54] N/A N/A N/A
6 months
None 13.53 [13.32–13.74] −0.12 [−0.31–0.07] 0.2118
Baseline only 13.43 [12.84–14.01] 0.62 [0.09–1.15] 0.0208
New onset 12.77 [12.14–13.41] −0.80 [−1.37–−0.24] 0.0055
Persistent 11.71 [11.20–12.22] −1.32 [−1.78–−0.86] 0.0000
12 months
None 13.62 [13.41–13.83] 0.09 [−0.10–0.28] 0.3652
Baseline only 13.32 [12.74–13.90] −0.11 [−0.63–0.42] 0.6904
New onset 11.79 [11.15–12.42] −0.99 [−1.56–−0.42] 0.0007
Persistent 11.85 [11.34–12.36] 0.14 [−0.31–0.60] 0.5360
30 months
None 13.37 [13.16–13.59] −0.24 [−0.44–−0.05] 0.0146
Baseline only 13.06 [12.45–13.66] −0.26 [−0.80–0.28] 0.3459
New onset 11.98 [11.34–12.61] 0.19 [−0.38–0.76] 0.5146
Persistent 11.06 [10.53–11.59] −0.79 [−1.27–−0.31] 0.0013
amodel adjusted for age, sex and baseline MMSE
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Table 4 Generalized Least Squares Mean (95 % Confidence Interval) Change in BADLa Over Time, by Depressive Symptom Change
over 1 Year
Depression symptom category Mean Change from previous measure P-value
Estimate 95 % CI Estimate 95 % CI
Baseline
None 13.92 [13.78–14.06] N/A N/A N/A
Baseline only 13.85 [13.45–14.25] N/A N/A N/A
New onset 13.94 [13.51–14.37] N/A N/A N/A
Persistent 13.46 [13.11–13.81] N/A N/A N/A
6 months
None 13.86 [13.72–14.00] −0.06 [−0.20–0.08] 0.4074
Baseline only 13.79 [13.39–14.19] −0.06 [−0.44–0.32] 0.7538
New onset 13.10 [12.67–13.53] −0.84 [−1.25–−0.43] 0.0001
Persistent 12.83 [12.48–13.17] −0.63 [−0.97–−0.30] 0.0002
12 months
None 13.81 [13.67–13.96] −0.05 [−0.19–0.09] 0.4870
Baseline only 13.63 [13.23–14.02] −0.16 [−0.54–0.22] 0.4068
New onset 13.09 [12.66–13.53] −0.01 [−0.42–0.41] 0.9781
Persistent 12.92 [12.58–13.27] 0.09 [−0.24–0.43] 0.5738
30 months
None 13.65 [13.50–13.80] −0.16 [−0.30–−0.02] 0.0268
Baseline only 13.42 [13.01–13.83] −0.21 [−0.60–0.18] 0.2942
New onset 13.20 [12.77–13.63] 0.10 [−0.31–0.52] 0.6213
Persistent 11.92 [11.55–12.28] −1.00 [−1.35–−0.65] 0.0000
amodel adjusted for age, sex and baseline MMSE
Fig. 2 Generalized Least Squares Mean (95 % Confidence Interval)
IADLa Over Time, by Depressive Symptom Change over 1 Year.
Legend/Footnote: aadjusted for age, sex, and baseline MMSE score
Fig. 3 Generalized Least Squares Mean (95 % Confidence Interval)
BADLa Over Time, by Depressive Symptom Change over 1 Year.
Legend/Footnote: aadjusted for age, sex, and baseline MMSE score
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programs. Conversely, impaired function might also lead
to depressive symptoms because of the perceived loss of
independence and mastery. We suspect the relationship
between the two is bi-directional. Finally, both depressive
symptoms and functional impairments might be second-
ary to factors such as small vessel cerebrovascular disease
[48], worse control of the patients CAD [49, 50], or the
presence (and impact) of other co-morbidities [51].
Strengths of our study include the longitudinal design
and minimal lost to follow-up despite a long duration
(30-month period), availability of detailed and repeat
measures of patients’ clinical, cognitive and functional
status, and inclusion of all three treatment options
(CABG, PCI and MT) following catheterization in the
3C cohort. Our interpretations are limited by the obser-
vational nature of the study and some uncertainty about
the clinical significance of the differences seen in IADL
and BADL scores. The relatively small number of cases
for a number of the categories limited our ability to
include numerous covariates in our adjusted analyses.
We were unable to explore sex and/or ethnic differences
in our analyses because most patients were male and
95 % were of European or unknown ethnicity. Due to
the absence of information, we were also not able to ex-
plore the influence of a previous history of depressive
symptoms, use of selected therapies (e.g., antidepres-
sants, psychotherapy, cardiac rehabilitation) or the avail-
ability of social support on the observed associations
between the evolution of depressive symptoms and func-
tional decline. At the same time, it is noteworthy that
there were few meaningful differences in the sociodemo-
graphic or clinical characteristics between patients with
baseline only compared with persistent depressive symp-
toms, despite clear differences in their functional out-
comes. As well, adjustment for variation in comorbidity
(in addition to age, sex and MMSE scores) did not alter
our findings. We believe the parsimonious approach we
took to modeling was appropriate in this study as
further adjustment for other covariates that were not ob-
served to vary by depressive symptom category or that
might be considered possible mediators of the associ-
ation between depressive symptom change and func-
tional decline may have posed a risk of unnecessary
adjustment (leading to a loss of precision in estimates)
or overadjustment bias (leading to a masking of relevant
exposure—outcome associations), respectively [52]. Fi-
nally, our findings may have limited generalizability to
other patient populations including CAD patient popula-
tions not undergoing invasive procedures, as all patients
underwent coronary catheterization.
Conclusions
In our sample of older CAD patients undergoing coronary
interventions, significant decreases in mean functional
scores over the 30 month follow-up were observed for
those with persistent (but not baseline only) depressive
symptoms. This suggests a one-time assessment of de-
pressive symptoms may be inadequate for determining
which patients are at high-risk for adverse functional out-
comes. Although there is little available research regarding
the impact of depression treatment on functional out-
comes, our findings illustrate the need for longer-term
monitoring and further large-scale evaluation of manage-
ment strategies (pharmaceutical and non-pharmaceutical)
for depression in CAD patients. A number of recent
studies have shown that a collaborative care model,
where both depression and cardiovascular disease are
simultaneously managed in the primary care setting
with the aid of a consulting psychiatrist, may result in a
significant (albeit modest) reduction in depressive
symptoms [53, 54]. Whether or not such multifaceted
interventions have a meaningful impact on the quality
of life and functional outcomes of older CAD patients
remains to be determined.
Main Bullet Points
 Patients with persistent depressive symptoms were
at greatest risk for worse functional status (assessed
as decline in instrumental [IADL] and basic [BADL]
activities of daily living) 30 months following
coronary interventions.
 Patients with no depressive symptoms or depressive
symptoms at baseline only showed relative stability
in their IADL and BADL functioning over time.
 Repeated screening for depression in older
patients with coronary artery disease offers
prognostic value and may facilitate the
implementation of targeted strategies to optimize
long-term functional outcomes.
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